Literature DB >> 8889728

Mutations in the gyrA and grlA genes of quinolone-resistant clinical isolates of methicillin-resistant Staphylococcus aureus.

M Takahata1, M Yonezawa, S Kurose, N Futakuchi, N Matsubara, Y Watanabe, H Narita.   

Abstract

The mutations in the quinolone-resistance determining regions (QRDR) of the gyrA, gyrB and grlA genes and in the norA gene from five clinical isolates of methicillin resistant Staphylococcus aureus (MRSA) were examined by DNA sequencing. The mutation from Ser84 to Leu in GyrA was associated with relatively high-level resistance to quinolones, whereas the mutation from Glu88 to Gly or Lys in GyrA was associated with low-level resistance to quinolones. Mutations of the grlA gene were observed at codon 80 (Ser80) or 84 (Glu84), independent of the mutations of gyrA. No mutations were observed in either the gyrB or norA genes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8889728     DOI: 10.1093/jac/38.3.543

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  12 in total

1.  In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone.

Authors:  M Takahata; J Mitsuyama; Y Yamashiro; M Yonezawa; H Araki; Y Todo; S Minami; Y Watanabe; H Narita
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC.

Authors:  F J Schmitz; M E Jones; B Hofmann; B Hansen; S Scheuring; M Lückefahr; A Fluit; J Verhoef; U Hadding; H P Heinz; K Köhrer
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

3.  Topoisomerase sequences of coagulase-negative staphylococcal isolates resistant to ciprofloxacin or trovafloxacin.

Authors:  D T Dubin; J E Fitzgibbon; M D Nahvi; J F John
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

4.  Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.

Authors:  T D Gootz; R P Zaniewski; S L Haskell; F S Kaczmarek; A E Maurice
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

5.  Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates.

Authors:  S Roychoudhury; C E Catrenich; E J McIntosh; H D McKeever; K M Makin; P M Koenigs; B Ledoussal
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

6.  In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.

Authors:  Mark E Jones; Ian A Critchley; James A Karlowsky; Renée S Blosser-Middleton; Franz-Josef Schmitz; Clyde Thornsberry; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

7.  Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models.

Authors:  Mahesh V Patel; Noel J De Souza; Shrikant V Gupte; Mohammad A Jafri; Sachin S Bhagwat; Yati Chugh; Habil F Khorakiwala; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

8.  Topoisomerase mutations in trovafloxacin-resistant Staphylococcus aureus.

Authors:  J E Fitzgibbon; J F John; J L Delucia; D T Dubin
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

9.  Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus.

Authors:  H Fukuda; S Hori; K Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

10.  Phenotypic and genotypic evaluation of fluoroquinolone resistance in clinical isolates of Staphylococcus aureus in Tehran.

Authors:  Marzieh Aligholi; Akbar Mirsalehian; Shahnaz Halimi; Hossein Imaneini; Morovat Taherikalani; Fereshteh Jabalameli; Parisa Asadollahi; Babak Mohajer; Alireza Abdollahi; Mohammad Emaneini
Journal:  Med Sci Monit       Date:  2011-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.